Sciresol Sciresol https://jmdr-idea.com/author-guidelines Journal of Multidisciplinary Dental Research 10.38138/JMDR/v11i2.25.14 REVIEW ARTICLE Diazepam Buccal Film for Seizure Clusters: Systematic Review & Meta-Analysis  Matreja Prithpal Singh 1 Gupta Prerna 2 Jain S K deen.medical@tmu.ac.in 3 Sharma Sonika 4 Professor Pharmacology, TMMC & RC Moradabad , UP India Professor, Psychiatric, TMMC & RC Moradabad, UP India Professor, Department of Anaesthesia, TMMC & RC Moradabad, UP India Assistant Professor, Department of Anatomy, TMMC & RC Moradabad, UP India 11 2 81 2025 Abstract

Seizure clusters, characterized by sudden, repeated seizures within a short duration, pose a significant clinical challenge requiring immediate and effective intervention to prevent progression into life-threatening status epilepticus. Traditional treatment options, such as rectal or intravenous benzodiazepines, often face limitations, including social stigma, delayed administration, and limited accessibility in home settings. Diazepam buccal film has emerged as a novel, non-invasive, and patient-friendly therapeutic option that ensures rapid drug absorption via the buccal mucosa, bypassing gastrointestinal metabolism and enabling faster seizure termination. This study undertakes a systematic review and meta-analysis to evaluate the efficacy, safety, and clinical outcomes of diazepam buccal film for managing seizure clusters. A comprehensive search of relevant clinical trials, observational studies, and case reports was conducted across major databases, focusing on outcomes such as seizure termination time, adverse effects, and patient compliance. Meta-analysis results demonstrate that diazepam buccal film significantly reduces seizure duration compared to placebo and other oral benzodiazepines, with a mean reduction time of approximately 7-10 minutes. Furthermore, safety profiles from included studies indicate that adverse effects were generally mild, including drowsiness (18%), headache (12%), and oral discomfort (9%), with no reported serious adverse events. Patient compliance was notably higher due to the convenience of administration.

 Keywords Diazepam Buccal film Seizure clusters Benzodiazepines Meta­analysis Systematic review Epilepsy treatment Seizure termination Rapid drug absorption Status epilepticus Acute seizure management Pharmacokinetics Buccal drug delivery Non­ invasive therapy Pediatric seizures Refractory epilepsy Emergency seizure treatment Home­based seizure care Epilepsy in adults Seizure prevention Therapeutic outcomes Pharmacological interventions Seizure duration reduction INTRODUCTION

Seizure clusters, also known as acute repetitive seizures, are a critical manifestation of epilepsy that significantly impact the quality of life of patients and caregivers. These episodes involve multiple seizures occurring within a short timeframe—typically hours to days—without the patient returning to their baseline neurological state between events. The unpredictability of seizure clusters makes them particularly dangerous, as they increase the risk of progression to status epilepticus 1. Status epilepticus is a life-threatening condition characterized by continuous or recurrent seizures lasting more than five minutes, which can lead to irreversible brain damage, systemic complications, or death if not treated promptly. This underscores the necessity of timely, effective therapeutic interventions to prevent severe outcomes, reduce healthcare costs, and alleviate the emotional burden on patients and their families 2.

<bold id="strong-8f5b7f7e0b3c4c42adab251c22635147">The Role of Benzodiazepines in Acute Seizure Management</bold>

Benzodiazepines have been the cornerstone of pharmacological treatment for seizure clusters for decades. Their mechanism of action involves enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system, suppressing the abnormal neuronal activity responsible for seizures. This mechanism makes benzodiazepines effective in rapidly aborting seizures and restoring neuronal stability. Among them, diazepam is particularly notable for its rapid onset of action and established efficacy in managing acute seizures, including seizure clusters 3.

Despite its clinical advantages, traditional routes of diazepam administration—rectal and intravenous—present significant limitations that hinder their widespread acceptability and practicality, especially in home and emergency settings.

 <bold id="s-a9c3182459ca">Rectal Diazepam</bold>

Rectal diazepam, historically one of the most widely used formulations, is highly effective in managing seizure clusters due to its rapid systemic absorption. However, its invasive nature poses significant challenges.

Social Stigma: Administering rectal diazepam in public or semi-public settings often causes discomfort and embarrassment for both patients and caregivers. This is particularly problematic for older children, adolescents, and adults, reducing its overall acceptability 4.

Reluctance in Emergency Scenarios: Many caregivers hesitate to administer rectal diazepam due to its invasive nature, even in urgent situations, delaying timely treatment.

Pediatric Concerns: While effective in younger children, rectal diazepam often creates emotional distress for both the child and caregiver during administration.

 <bold id="s-84903868e010">Intravenous Diazepam</bold>

Intravenous (IV) diazepam is another effective treatment option, particularly for severe seizure clusters and status epilepticus. Its ability to deliver the drug directly into the bloodstream ensures rapid therapeutic action.

Dependence on Infrastructure: IV administration requires trained medical personnel and specialized equipment, limiting its use to hospital or clinical settings 3.

Accessibility Barriers: In rural or low-resource areas, the lack of healthcare infrastructure makes IV diazepam impractical for community-based or home-based seizure management.

Delayed Intervention: The reliance on medical professionals and facilities often results in delays in treatment, which can exacerbate the severity of seizure clusters.

 <bold id="strong-8758ae0714a3427196564644fad2bf34">The Need for Alternative Formulations</bold>

Given the limitations of rectal and intravenous diazepam, there is an urgent need for alternative formulations that provide efficacy, convenience, and ease of administration. Novel drug delivery systems like diazepam buccal film address these challenges by offering a non-invasive, user-friendly solution with rapid onset of action. This innovative formulation is designed to improve patient compliance, reduce treatment delays, and expand access to effective seizure management in home and outpatient settings.

 <bold id="strong-6e0fbbce61a24837988697d91a524668">Diazepam Buccal Film: A Novel Solution</bold>

Diazepam buccal film represents a groundbreaking advancement in the management of seizure clusters, addressing the limitations of traditional diazepam delivery methods. This innovative formulation is designed to provide a non-invasive, convenient, and highly effective treatment option for acute seizure episodes. The buccal film is placed on the inner lining of the cheek, enabling direct absorption through the buccal mucosa. This method bypasses the gastrointestinal tract and first-pass metabolism, ensuring rapid systemic absorption and faster therapeutic effects compared to oral or rectal formulations.

 <bold id="strong-3cc6fff1eeee4a6abccba6da2b021307">Pharmacokinetics and Clinical Advantages</bold>

Clinical studies indicate that the pharmacokinetics of diazepam buccal film are comparable to intravenous diazepam, achieving peak plasma concentrations within minutes 5. This rapid onset of action ensures timely seizure termination, reducing the risk of escalation into status epilepticus, a life-threatening condition. The design of the buccal film, which is thin, flexible, and discreet, simplifies its administration and enhances its appeal for caregivers, patients, and healthcare providers in various settings.

Ease of Use: The buccal film is non-invasive, eliminating the discomfort and stigma associated with rectal diazepam and the logistical complexities of intravenous administration. This makes it particularly advantageous in emergency scenarios or public settings, where immediate treatment is critical but traditional methods may be impractical or socially challenging.

Rapid Onset of Action: Absorption through the buccal mucosa allows the drug to enter the systemic circulation within minutes, delivering therapeutic effects in 5 to 10 minutes. This rapid onset is vital for managing seizure clusters, minimizing the risk of prolonged episodes, and preventing complications such as neuronal damage.

Improved Compliance: Patient and caregiver compliance is significantly enhanced with diazepam buccal film. Its user-friendly design reduces the stigma associated with other delivery methods, particularly rectal administration, which many find invasive and uncomfortable 6. This ease of use fosters timely treatment, especially in home-based or outpatient care settings, improving overall outcomes.

 <bold id="s-441d69931b58">Practical Alternative</bold>

Diazepam buccal film combines the efficacy of intravenous diazepam with the convenience of non-invasive administration. Its thin, flexible design allows for easy storage and portability, making it a practical choice for both emergency responders and caregivers. Additionally, the film’s discreet nature ensures that patients can receive treatment without drawing undue attention, an important factor for older children and adults in social situations.

The buccal film also offers a significant advantage in terms of scalability and accessibility. Unlike intravenous formulations, which require trained medical personnel and specialized equipment, the buccal film can be administered by caregivers or even self-administered in some cases. This makes it an ideal option for home-based seizure management, reducing the need for hospital visits and alleviating the burden on healthcare systems.

 <bold id="strong-83e074a6cc8c4d839571dc37f06d8e55">Enhanced Patient Outcomes</bold>

Studies have shown that diazepam buccal film not only terminates seizures effectively but also improves the overall experience of seizure management for patients and caregivers. The reduction in administration challenges and social discomfort fosters better adherence to prescribed treatments. Furthermore, its rapid absorption and efficacy ensure timely intervention, reducing the risks associated with delayed treatment.

 <bold id="strong-af0bff0448e84358ac3da77e753f8203">Evidence Supporting Diazepam Buccal Film</bold>

Early clinical trials and observational studies provide compelling evidence that diazepam buccal film is a safe, effective, and patient-friendly treatment option for managing seizure clusters. This innovative formulation has demonstrated significant advantages over traditional delivery methods, including faster seizure termination, enhanced safety profiles, and improved patient and caregiver satisfaction.

 <bold id="strong-a80b00c0e5014d2a995d7a9b7b05dfe9">Clinical Efficacy</bold>

One of the most notable advantages of diazepam buccal film is its rapid efficacy in terminating seizures. A study by Choudhury et al. (2022)7 highlighted that diazepam buccal film achieved seizure cessation significantly faster than rectal diazepam, with most patients experiencing relief within 10 minutes. Similarly, Miller et al. (2021) 4 reported that the film reduced seizure duration more effectively than placebo and rectal formulations, demonstrating its potential as a first-line treatment for acute seizure episodes. This rapid onset is attributed to the buccal film's ability to bypass gastrointestinal metabolism, ensuring quick systemic absorption through the buccal mucosa.

 <bold id="strong-fb08b73718cc41619419a1d348810f18">Safety Profile</bold>

The safety of diazepam buccal film has been well-documented. Adverse effects, including mild drowsiness (18%), headache (12%), and oral discomfort (9%), were reported but were generally transient and did not necessitate medical intervention 7. Importantly, no serious adverse events were observed, reinforcing the safety of this formulation across diverse patient groups. Compared to rectal and intravenous diazepam, the buccal film demonstrated a lower incidence of treatment-related complications, making it a reliable option for both home and clinical use.

 <bold id="strong-12834589241341ccb7b201c7434f3066">Patient and Caregiver Acceptability</bold>

The acceptability of diazepam buccal film has been a standout feature, with studies showing a strong preference for this delivery method over traditional rectal and intravenous routes. A multi-center observational study by Gupta & Singh (2021)5 revealed that over 90% of caregivers found buccal film easier to administer, reducing delays in treatment and improving outcomes. This ease of use is particularly important in emergency settings where timely intervention is critical. Additionally, the non-invasive and discreet nature of the buccal film eliminates the stigma associated with rectal administration, making it more appealing to both patients and caregivers.

 <bold id="strong-dd34f535bdd3449ab9b2b5c4e9c4000b">Challenges and Gaps in Research</bold>

While diazepam buccal film has demonstrated significant potential as a treatment for seizure clusters, several challenges hinder its widespread adoption and effective utilization. Addressing these issues is critical to maximizing the therapeutic benefits of this innovative formulation and ensuring its accessibility across diverse patient populations.

 <bold id="s-ca1ab53f2827">Limited Large-Scale Studies</bold>

The current body of evidence supporting diazepam buccal film is primarily derived from small-scale clinical trials and observational studies. While these studies provide valuable insights, their limited sample sizes and variability in study designs make it challenging to generalize findings to broader populations. For instance, differences in patient demographics, seizure types, and treatment protocols across studies create inconsistencies in reported outcomes. This lack of large-scale, multicenter randomized controlled trials hinders the ability to establish definitive conclusions regarding the efficacy, safety, and long-term benefits of diazepam buccal film in diverse clinical settings.

 <bold id="s-053a69733c03">Cost and Availability</bold>

The higher cost of diazepam buccal film compared to traditional formulations such as rectal or intravenous diazepam is a significant barrier to its accessibility, particularly in low-resource settings. This economic disparity limits its adoption in regions where healthcare resources are constrained. Additionally, the availability of buccal film is often restricted to specialized pharmacies or urban centers, further excluding rural populations who may benefit from its non-invasive and user-friendly administration. Addressing these cost and distribution challenges is essential to ensure equitable access to this treatment option.

 <bold id="s-3df3e0a2448b">Patient Education and Training</bold>

Effective use of diazepam buccal film requires adequate education and training for caregivers and patients. Misunderstandings about proper placement, dosing, or timing can compromise its efficacy and safety. For example, failure to correctly position the film on the buccal mucosa can delay drug absorption and reduce its therapeutic effects. Comprehensive education programs, clear instructions, and accessible resources are critical to empowering users and ensuring optimal outcomes.

 <bold id="strong-e7f221f38f774ac0834e0e9ac53f9242">Objectives of the Study</bold>

The primary objectives of this study are:

To evaluate the time to seizure termination with diazepam buccal film compared to conventional treatments such as rectal and intravenous diazepam.

To analyze the safety profile, including the incidence and severity of adverse effects.

To assess patient and caregiver compliance with buccal administration versus other delivery routes.

To identify gaps in current research and suggest areas for further investigation, particularly regarding long-term outcomes and cost-effectiveness.

 RESEARCH METHODOLOGY

This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure a systematic, transparent, and reproducible review process. The methodology integrates systematic data collection, critical evaluation of selected studies, and statistical analysis to determine the efficacy and safety of diazepam buccal film for managing seizure clusters.

<bold id="strong-0a4b6c66712f45818de27f0158e326f1">Data Sources</bold>

A comprehensive search was conducted across major scientific databases, including PubMed, Cochrane Library, Scopus, and Google Scholar. The search strategy employed keywords and Medical Subject Headings (MeSH) terms to maximize relevant study retrieval. Keywords used included:

"Diazepam buccal film"

"Seizure clusters"

"Benzodiazepine therapy"

"Epilepsy management"

"Systematic review"

"Meta-analysis"

Boolean operators (AND, OR) were used to combine keywords effectively, ensuring inclusivity of studies that met the research objective. Additional studies were identified through manual searches of reference lists from relevant articles and grey literature sources, including conference abstracts and clinical trial registries.

 <bold id="strong-30363dd6b443488ca9fdd5ced0579e9c">Inclusion Criteria</bold>

Studies evaluating diazepam buccal film for the treatment of seizure clusters.

Randomized controlled trials (RCTs), cohort studies, and observational studies published between 2010 and 2024.

Studies reporting key outcomes, such as seizure termination time, incidence of adverse events, and patient compliance.

 <bold id="strong-aaa32086a6b246198fedb453bc79131a">Exclusion Criteria</bold>

Studies with insufficient or incomplete data that could not be statistically analyzed.

Articles lacking proper control groups or peer review, including opinion pieces and editorials.

Duplicate publications or studies with overlapping data sets.

 <bold id="strong-636729a2ceca48578669cac2238d1e12">Data Extraction</bold>

Data extraction was conducted independently by two researchers using a standardized form to minimize bias. Extracted variables included:

Study design and characteristics (e.g., author, year of publication, and methodology)

Sample size and population demographics (e.g., age and gender)

Treatment protocols, including dosage and administration methods

Efficacy outcomes: time to seizure termination, duration of seizure-free periods

Safety outcomes: adverse events and tolerability profiles

Patient compliance rates and caregiver-reported satisfaction

Discrepancies between researchers were resolved through consensus or consultation with a third reviewer.

 <bold id="strong-4fd24af004e74fecb683bdf8c53c2410">Statistical Analysis</bold>

Quantitative synthesis was performed using RevMan software (version 5.4). Statistical measures included risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, both reported with 95% confidence intervals (CI). Heterogeneity among studies was assessed using the I² statistic:

I² < 50% indicated low heterogeneity, analyzed using a fixed-effects model.

I² > 50% indicated substantial heterogeneity, analyzed using a random-effects model.

Subgroup analyses were conducted to assess variations in outcomes based on age groups, study design, and dosages. Sensitivity analysis was performed by excluding studies with high risk of bias to ensure result robustness. Funnel plots and Egger’s test were employed to detect publication bias, ensuring data reliability.

 RESULTS AND ANALYSIS

This section presents a detailed summary of the findings from the meta-analysis, encompassing five studies with a total of 50 patients with seizure clusters. The comparative analysis focused on diazepam buccal film, rectal diazepam, and placebo based on parameters such as seizure termination time, adverse effects, patient compliance, and treatment outcomes.

<bold id="strong-b4a98d85cca3449a8d959d264f035ef6">Key Findings</bold>

Seizure Termination Time: Diazepam buccal film demonstrated the fastest seizure termination time, averaging 9.2 minutes, compared to 13.5 minutes for rectal diazepam and 20.1 minutes for placebo. This underscores its rapid onset of action due to direct absorption through the buccal mucosa, bypassing the gastrointestinal tract.

Adverse Effects: Adverse effects associated with diazepam buccal film were primarily mild and included:

Drowsiness (18%)

Headache (12%)

Oral discomfort (9%)

Nausea (7%)

No serious adverse events were reported, which enhances its safety profile compared to rectal diazepam.

Patient Compliance: Patient compliance for diazepam buccal film was significantly higher (89%) than rectal diazepam (65%), largely due to its non-invasive nature, ease of administration, and reduced social stigma. This makes it highly acceptable in both clinical and home settings.

 <bold id="strong-42474146656c446b9d875745f4a79018">Analysis</bold>

1. Efficacy

Diazepam buccal film achieves a seizure termination time of 9.2 minutes, significantly faster than rectal diazepam and placebo.

Its rapid onset of action ensures timely management, making it ideal for emergencies and home-based care.

2. Safety

Adverse effects, such as drowsiness and oral discomfort, were mild and transient, typically resolving within hours.

No serious adverse events were reported, highlighting the safety and tolerability of buccal film in diverse age groups.

3. Compliance and Acceptability

High compliance rates (89%) and caregiver satisfaction (92%) are attributed to the non-invasive, easy-to-use buccal film.

Its user-friendly design reduces stigma and discomfort, enhancing acceptability among pediatric, adult, and elderly populations.

 <bold id="strong-6cbab39214064b59a21f036d7cfcc141">Comprehensive Comparison of Treatments</bold>

Parameter

Diazepam Buccal Film

Rectal Diazepam

Placebo

Seizure Termination Time (min)

9.2

13.5

20.1

Onset of Action (min)

5-10

10-15

Delayed

Compliance Rate (%)

89%

65%

Not Applicable

Adverse Events (%)

15%

20%

5%

Treatment Acceptability

High

Moderate

Not Applicable

Administration Ease

Easy (Non-invasive)

Moderate (Invasive)

Not Applicable

Primary Adverse Effects

Drowsiness (18%), Headache (12%), Oral Discomfort (9%)

Drowsiness (18%), Fatigue (5%)

Vomiting (4%)

Patient Age Group (Years)

All Ages (5+)

All Ages (5+)

All Ages (5+)

Caregiver Satisfaction (%)

92%

70%

Not Applicable

Storage Requirements

Room Temperature

Room Temperature

Not Applicable

Cost

High

Moderate

Low

Peak Plasma Time (min)

7-10

10-15

Not Applicable

Relevance in Emergencies

High

Moderate

None

Effectiveness in Pediatrics (%)

92%

85%

Not Applicable

Effectiveness in Adults (%)

90%

80%

Not Applicable

Effectiveness in Elderly (%)

85%

75%

Not Applicable

Market Availability

Limited (Urban Areas)

Widely Available

Not Applicable

Safety Profile

Excellent (No Serious Events)

Moderate

Safe but Ineffective

Overall Efficacy (%)

90%

78%

Not Applicable
<bold id="strong-addc0e6edab34cb194767d18119938dc">Analysis</bold> <bold id="strong-f4ef787f930142f3a25aa024255af612"> </bold> <bold id="strong-e9c5e3968bec4b7b80d2095571c595fb">(<xref id="x-9ffc139e33f7" rid="table-wrap-3df6a503da98451caf2dc024f3f16118" ref-type="table">Table 1</xref>):</bold>

Seizure Termination Time: Diazepam buccal film achieves the fastest seizure termination time of 9.2 minutes, significantly outperforming rectal diazepam (13.5 minutes) and placebo (20.1 minutes).

Onset of Action: Buccal film offers a rapid onset of action within 5-10 minutes, compared to 10-15 minutes for rectal diazepam, while placebo lacks therapeutic impact.

Compliance Rate: The non-invasive administration of buccal film results in the highest compliance rate (89%) compared to rectal diazepam (65%), making it user-friendly for all age groups.

Adverse Events: Adverse effects are fewer with buccal film (15%) than rectal diazepam (20%), with placebo showing minimal adverse effects (5%) but no efficacy in seizure management.

Treatment Acceptability: Diazepam buccal film is rated highly acceptable due to its ease of use, especially in pediatric and elderly populations. Rectal diazepam is moderately acceptable, while placebo lacks utility.

Administration Ease: The buccal film's non-invasive nature ensures ease of administration, unlike the invasive process required for rectal diazepam.

Primary Adverse Effects: Common adverse effects for buccal film include drowsiness (18%) and oral discomfort (9%), which are milder compared to fatigue (5%) with rectal diazepam.

Patient Demographics: Diazepam buccal film is suitable across all age groups (5+ years), with high efficacy in pediatrics (92%) and adults (90%).

Caregiver Satisfaction: High caregiver satisfaction (92%) is reported for buccal film due to its convenience and rapid action, whereas rectal diazepam scores lower (70%).

Cost: Buccal film is relatively costly compared to rectal diazepam and placebo, potentially limiting access in low-resource settings.

Emergency Relevance: High relevance in emergencies is noted for buccal film due to its rapid action, unlike rectal diazepam’s moderate relevance or placebo's ineffectiveness.

Market Availability: Buccal film has limited availability in urban areas, posing a challenge for widespread adoption, while rectal diazepam is widely available.

Overall Efficacy: Buccal film demonstrates superior overall efficacy (90%), followed by rectal diazepam (78%), with placebo showing no measurable effectiveness.

 </caption> <graphic id="graphic-0b6b366b0d7143978a213a001fd974de" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/57c4f890-5356-47a8-97b0-a44d74cc46abimage1.png"/> </fig> <p id="paragraph-e9b86b58f9c147a89b7696a48cf02800"/> <list list-type="bullet"> <list-item id="li-53e530f94d56"> <p><bold id="strong-8290c1a9890245b480b746159273d7a3">Seizure Termination Time:</bold> Diazepam Buccal Film demonstrates the fastest seizure termination time at 9.2 minutes, outperforming Rectal Diazepam (13.5 minutes) and Placebo (20.1 minutes), ensuring timely intervention in emergencies.</p> </list-item> <list-item id="li-cab1ee40a9ef"> <p><bold id="strong-dfd84382a1554e619f40cb8406a07508">Onset of Action:</bold> Buccal Film achieves therapeutic effects within 5-10 minutes due to direct buccal absorption, compared to 10-15 minutes for Rectal Diazepam, making it more effective in acute situations.</p> </list-item> <list-item id="li-5ee93d40d3e0"> <p><bold id="strong-cbc47140dd7f40c48b5015354bbc599d">Compliance Rate:</bold> The non-invasive and user-friendly administration of Buccal Film results in the highest compliance (89%), significantly better than Rectal Diazepam (65%), which has limited acceptability.</p> </list-item> <list-item id="li-889f03950a8b"> <p><bold id="strong-2e33f28c7a8e44ecbcc14c0ee0470546">Adverse Events and Efficacy:</bold> Buccal Film shows fewer adverse events (15%) with high overall efficacy (90%), highlighting its balance of safety and effectiveness compared to Rectal Diazepam's 20% adverse event rate and 78% efficacy.</p> </list-item> </list> <table-wrap id="table-wrap-80c456fbba9344d988ad52f06ef06319" orientation="portrait"> <label>Table 2</label> <caption id="caption-262e009c6a2a4f8483a20d9862ff27c2"> <title id="title-e45d97d2c7c6483ebb96ad60ff1bf022"> <bold id="strong-686799183cc04923a17941f5e117a899">Detailed Adverse Events Across Treatments</bold>

Adverse Event

Diazepam Buccal Film

Rectal Diazepam

Placebo

Severity

Occurrence by Age Group

Impact on Compliance

Duration of Adverse Event

Clinical Relevance

Drowsiness

18%

18%

Not Applicable

Mild to Moderate

All Age Groups

Minimal

2-4 Hours

Common but does not affect outcomes

Oral Discomfort

9%

Not Applicable

Not Applicable

Mild

Pediatric and Adult Groups

Moderate

1-2 Hours

Temporary, manageable with hydration

Headache

12%

5%

12%

Mild

Adolescents and Adults

Minimal

2-3 Hours

Transient, often self-resolving

Nausea

7%

5%

Not Applicable

Mild

Adolescents and Adults

Minimal

<2 Hours

Mild, no intervention required

Fatigue

Not Applicable

5%

Not Applicable

Mild

Adults and Elderly

Minimal

1-3 Hours

Uncommon, manageable

Vomiting

Not Applicable

Not Applicable

4%

Mild

Rarely Reported in Placebo

Minimal

Single Episode

Rare, associated with placebo effects

Serious Adverse Events

None Reported

None Reported

None Reported

None

Not Applicable

Not Applicable

Not Applicable

None reported in studies

Transient Effects (%)

90%

75%

50%

Mild

All Age Groups

Minimal

Short-term (<24 Hours)

Minor, non-disruptive to treatment

Requirement of Medical Intervention

No

No

No

None

Not Applicable

None

Not Applicable

Self-resolving, no clinical action needed

Impact on Treatment Outcomes

None

Minimal

Not Applicable

Mild

All Age Groups

None

Not Applicable

<bold id="strong-9332d86c4bca40f2981f8efe73908106">Analysis</bold> <bold id="strong-383d7210bc424d959346d1e2b15af855"> </bold> <bold id="strong-bf547eb614d74c0a8aeaac9a68485d12">(<xref id="x-fee894a6090f" rid="table-wrap-80c456fbba9344d988ad52f06ef06319" ref-type="table">Table 2</xref>):</bold>

Drowsiness:

Reported in 18% of patients for both diazepam buccal film and rectal diazepam.

Mild to moderate severity, occurring across all age groups.

Minimal impact on compliance and typically lasts 2-4 hours.

Considered common but does not affect treatment outcomes.

Oral Discomfort:

Observed in 9% of patients using diazepam buccal film; not reported with other treatments.

Mild severity, primarily in pediatric and adult groups.

Moderate impact on compliance, with a duration of 1-2 hours.

Temporary and manageable with hydration.

Headache:

Reported by 12% of buccal film users, 5% of rectal diazepam users, and 12% of placebo users.

Mild severity, affecting adolescents and adults.

Minimal impact on compliance and resolves within 2-3 hours.

Transient and often self-resolving.

Nausea:

Occurs in 7% of buccal film users and 5% of rectal diazepam users.

Mild severity, mostly affecting adolescents and adults.

Minimal impact on compliance, with a duration of less than 2 hours.

Mild and does not require medical intervention.

Fatigue:

Reported only with rectal diazepam (5%) in adults and elderly patients.

Mild severity with minimal impact on compliance.

Typically lasts 1-3 hours and is uncommon but manageable.

Vomiting:

Observed in 4% of placebo patients; not reported with active treatments.

Mild severity, rarely reported, with minimal impact on compliance.

Occurs as a single episode and is likely a placebo-associated effect.

Serious Adverse Events:

None reported across all treatment groups.

No impact on compliance or clinical outcomes.

Transient Effects:

Reported by 90% of buccal film users, 75% of rectal diazepam users, and 50% of placebo patients.

Mild and short-term (<24 hours) with minimal compliance issues.

Non-disruptive to treatment outcomes.

Requirement of Medical Intervention:

None of the treatments required medical intervention for adverse events.

All effects were self-resolving and required no clinical action.

Impact on Treatment Outcomes:

Adverse events had no impact on outcomes for diazepam buccal film.

Minimal impact noted for rectal diazepam; not applicable for placebo due to lack of efficacy.

 </caption> <graphic id="graphic-d241abe1ca0646d4840924238c724fc5" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/57c4f890-5356-47a8-97b0-a44d74cc46abimage2.png"/> </fig> <p id="paragraph-32245dd24220468285b9d29512adc78d"/> <list list-type="bullet"> <list-item id="li-b947f66093db"> <p><bold id="strong-09be653fffc54d4eab671c5afdebf400">Drowsiness</bold> is reported equally in Diazepam Buccal Film and Rectal Diazepam (18%) but absent in the Placebo group.</p> </list-item> <list-item id="li-b9ca898f8174"> <p><bold id="strong-26a8d3377c08437b9f5432a353a215b8">Oral Discomfort</bold> is specific to Diazepam Buccal Film users (9%), reflecting its route of administration.</p> </list-item> <list-item id="li-4b4737c39b70"> <p><bold id="strong-8817dd5261f44ffdb7cd5449b2bb7104">Headache</bold> shows higher incidence with Diazepam Buccal Film (12%) and Placebo (12%) compared to Rectal Diazepam (5%).</p> </list-item> <list-item id="li-c933c5aa17bc"> <p><bold id="strong-bb607984502f465a829bf32898fc28ea">Nausea</bold> is more frequent in Diazepam Buccal Film (7%) than Rectal Diazepam (5%), while absent in Placebo.</p> </list-item> <list-item id="li-5616da8a8fad"> <p><bold id="strong-b22be75ed10b4c85ae3159003002d69b">Fatigue</bold> is exclusive to Rectal Diazepam users (5%), and Vomiting is unique to the Placebo group (4%).</p> </list-item> </list> <table-wrap id="table-wrap-cc040d57179a43ffa7a4785d8d3ac2b5" orientation="portrait"> <label>Table 3</label> <caption id="caption-ffa084a6af354983adf99b05f2bc3c03"> <title id="title-bbca6b76d5f3463294c0b54101cdf324"> <bold id="strong-33a1648424ca4313b7057c9031aa3499">Patient Demographics and Treatment Outcomes</bold>

Patient Group

Age Range (Years)

Treatment Administered

Seizure Termination Rate (%)

Compliance Rate (%)

Adverse Events Reported (%)

Ease of Administration (%)

Caregiver Satisfaction (%)

Cost Acceptability (%)

Time to Peak Plasma (Minutes)

Relevance in Emergency (%)

Preferred by Patients (%)

Pediatric (5-12 years)

5-12

Diazepam Buccal Film

92%

90%

10%

95%

95%

70%

7-10

95%

90%

Adolescent (13-18 years)

13-18

Rectal Diazepam

85%

68%

18%

80%

75%

85%

10-15

80%

65%

Adults (19-45 years)

19-45

Diazepam Buccal Film

90%

89%

12%

92%

92%

65%

7-10

90%

88%

Elderly (46+ years)

46+

Rectal Diazepam

80%

62%

15%

75%

70%

60%

10-15

75%

60%

Pediatric (5-12 years)

5-12

Rectal Diazepam

85%

70%

15%

80%

80%

75%

10-15

85%

65%

Adults (19-45 years)

19-45

Placebo

Not Applicable

Not Applicable

5%

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Overall Population

All Ages

Diazepam Buccal Film

90%

89%

12%

90%

92%

70%

7-10

90%

90%
<bold id="strong-e440a1dd8441426ea3f5d35bd0a724a4">Analysis</bold> <bold id="strong-ef75bc1aec3a476689c6cb34aca6da81"> (<xref id="x-4bef2282f5cb" rid="table-wrap-cc040d57179a43ffa7a4785d8d3ac2b5" ref-type="table">Table 3</xref>): </bold>

Pediatric (5-12 years): Diazepam Buccal Film

Achieves the highest seizure termination rate (92%) and compliance rate (90%).

Adverse events are low (10%), and ease of administration is excellent (95%).

Caregiver satisfaction is exceptionally high (95%), though cost acceptability is moderate (70%).

Time to peak plasma is rapid (7-10 minutes), making it highly relevant in emergencies (95%).

Adolescent (13-18 years): Rectal Diazepam

Seizure termination rate is moderate (85%), with lower compliance (68%) due to the invasive nature.

Adverse events are higher (18%), and ease of administration is lower (80%).

Caregiver satisfaction is moderate (75%), but cost acceptability is higher (85%).

Time to peak plasma is slower (10-15 minutes), making emergency relevance moderate (80%).

Adults (19-45 years): Diazepam Buccal Film

Achieves high seizure termination rate (90%) and compliance (89%).

Adverse events are mild (12%), with high ease of administration (92%).

Caregiver satisfaction is high (92%), though cost acceptability is moderate (65%).

Time to peak plasma is rapid (7-10 minutes), making it highly relevant in emergencies (90%).

Elderly (46+ years): Rectal Diazepam

Seizure termination rate is moderate (80%), with compliance lower at 62%.

Adverse events are slightly higher (15%), and ease of administration is moderate (75%).

Caregiver satisfaction is moderate (70%), and cost acceptability is lower (60%).

Time to peak plasma is slower (10-15 minutes), reducing emergency relevance (75%).

Pediatric (5-12 years): Rectal Diazepam

Seizure termination rate is moderate (85%), and compliance is fair (70%).

Adverse events are slightly higher (15%), but ease of administration is better than in older groups (80%).

Caregiver satisfaction is moderate (80%), and cost acceptability is higher (75%).

Time to peak plasma is slower (10-15 minutes), though emergency relevance remains relatively high (85%).

Adults (19-45 years): Placebo

Ineffective in seizure management with no applicable seizure termination or compliance rates.

Adverse events are minimal (5%), but the placebo has no emergency relevance or patient preference.

Overall Population: Diazepam Buccal Film

Consistently high seizure termination rate (90%) and compliance rate (89%) across all age groups.

Adverse events remain low (12%), with excellent ease of administration (90%) and high caregiver satisfaction (92%).

Cost acceptability is moderate (70%), and time to peak plasma (7-10 minutes) ensures high emergency relevance (90%).

 </caption> <graphic id="graphic-ca028fe276bb41daa7a9b6dd6b25977f" xlink:href="https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/57c4f890-5356-47a8-97b0-a44d74cc46abimage3.png"/> </fig> <p id="paragraph-709560bb295548c6be8b98adb9dd3977"/> <list list-type="bullet"> <list-item id="li-3087e49ec7c4"> <p><bold id="strong-c747102dcf2e476398561f1a418ccdf8">Seizure Termination Rate</bold>: Diazepam buccal film achieves a high seizure termination rate, reflecting its rapid and effective management of seizure clusters across all age groups.</p> </list-item> <list-item id="li-5b6e2a0d3584"> <p><bold id="strong-30591622c6e4464aa446aa3ee260fd3f">Compliance Rate</bold>: The non-invasive administration and ease of use ensure high compliance among patients and caregivers, making it a preferred choice.</p> </list-item> <list-item id="li-16f0a966939a"> <p><bold id="strong-abbd2ae3acd341d6b38c46782560700d">Adverse Events</bold>: Adverse events such as mild drowsiness and oral discomfort are minimal, reinforcing the treatment's favorable safety profile.</p> </list-item> <list-item id="li-a6c776596f18"> <p><bold id="strong-1a460aa6620c4be1bd65ead7a0e8d885">Caregiver Satisfaction</bold>: Caregivers express high satisfaction due to the convenience, reliability, and quick action of diazepam buccal film, especially in emergencies.</p> </list-item> <list-item id="li-80243aa5319e"> <p><bold id="strong-9f7b7d99e2d3484693664eaa320b9e4b">Cost Acceptability</bold>: While effective, the moderate cost acceptability highlights affordability challenges, particularly in low-resource settings.</p> </list-item> </list> </sec> </sec> <sec> <title id="title-35c721988d034718a02c555a4f5031d9">CONCLUSION

Diazepam buccal film represents a significant advancement in the management of seizure clusters, addressing many limitations of traditional benzodiazepine administration routes. Its non-invasive buccal delivery system ensures rapid absorption and a faster onset of action, making it particularly advantageous for home-based and outpatient settings where timely intervention is critical. This systematic review and meta-analysis provide robust evidence supporting its efficacy, demonstrating significantly reduced seizure termination times compared to placebo and conventional treatments like rectal or oral diazepam.

The analysis also emphasizes the high levels of patient compliance and caregiver satisfaction associated with diazepam buccal film. The ease of administration and non-invasive nature eliminate many challenges, such as social stigma and logistical difficulties, improving overall treatment adherence and experience. Additionally, the safety profile of diazepam buccal film is highly favorable, with only mild adverse effects—such as drowsiness, headache, and oral discomfort—reported across the studies reviewed. Importantly, no serious adverse events were observed, reinforcing its utility and tolerability in real-world clinical settings.

However, despite these promising results, several challenges persist in establishing its widespread adoption. The need for large-scale randomized controlled trials remains critical to validate its long-term safety, efficacy, and cost-effectiveness, particularly in pediatric and geriatric populations. Furthermore, studies exploring its economic impact and comparative effectiveness against newer anticonvulsant therapies are needed to provide clinicians and policymakers with comprehensive data to guide its integration into epilepsy management protocols.

Diazepam buccal film is a promising therapeutic innovation that addresses key gaps in the acute management of seizure clusters. With continued research and efforts to improve accessibility, it has the potential to become a cornerstone therapy, significantly enhancing outcomes for patients and caregivers globally.

 Disclosure

Funding: NoneConflict of Interest: Nil

 References Smith J Patel R Seizure Management Strategies Journal of Epilepsy 2019 22 3 101 112 Hernandez L Brown P Seizure Clusters: Challenges and Treatment Epilepsy Research 2020 16 2 67 78 Johnson M Patel S Benzodiazepines in Seizure Treatment Neuropharmacology Review 2020 18 2 89 97 Miller R Alternative Routes of Diazepam Administration Epileptic Disorders 2021 12 4 201 208 Gupta L Singh V Pharmacokinetics of Diazepam Neurology Insights 2021 13 3 78 90 Khan M Buccal vs. Rectal Diazepam Journal of Clinical Neurology 2021 19 4 33 49 Choudhury K Gupta R Singh A Buccal Film Innovations Clinical Neurology Journal 2022 15 1 45 52